VISTAGEN THERAPEUTICS, INC. (VTGN) Total liabilities 2017–2026
VISTAGEN THERAPEUTICS, INC. (VTGN) total liabilities at each fiscal year-end, per SEC filings.
$13.0MFY2026 · since FY2017: $3.1M → $13.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $13.0M | -6.5% |
| FY2025 | $14.0M | +48.9% |
| FY2024 | $9.4M | +4.0% |
| FY2023 | $9.0M | -9.3% |
| FY2022 | $9.9M | -39.1% |
| FY2021 | $16.3M | +41.7% |
| FY2020 | $11.5M | — |
| FY2018 | $4.4M | +40.9% |
| FY2017 | $3.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VTGN financial trends
VTGN RevenueVTGN Net incomeVTGN Net marginVTGN Gross profitVTGN Gross marginVTGN Operating incomeVTGN Operating marginVTGN Operating cash flowVTGN Free cash flowVTGN Capital expendituresVTGN Return on equityVTGN Stock buybacksVTGN Dividends paidVTGN Total assetsVTGN Shareholders’ equityVTGN overview →